Your browser doesn't support javascript.
loading
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety.
Shao, Yu-Yun; Feng, Yin-Hsun; Yen, Chia-Jui; Yang, Tsai-Sheng; Shen, Ying-Chun; Chao, Yee; Chen, Jen-Shi; Su, Ching-Yen; Chen, Wei-Jen; Hsiang, Hwa-Lin; Hsu, Chih-Hung.
Afiliación
  • Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address: yuyunshao@gmail.
  • Feng YH; Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Yang TS; Department of Hematology-Oncology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
  • Shen YC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Chen JS; Department of Hematology-Oncology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
  • Su CY; Medical Division, Roche Products Ltd, Taipei, Taiwan.
  • Chen WJ; Medical Division, Roche Products Ltd, Taipei, Taiwan.
  • Hsiang HL; Medical Division, Roche Products Ltd, Taipei, Taiwan.
  • Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
J Formos Med Assoc ; 121(12): 2430-2437, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36153210
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Límite: Humans / Middle aged Idioma: En Revista: J Formos Med Assoc Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Límite: Humans / Middle aged Idioma: En Revista: J Formos Med Assoc Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article